Form 4: RAPT Therapeutics Director Linda Kozick Granted Significant Stock Options

RAPT Therapeutics, Inc. Director Linda Kozick was granted 257,832 stock options with an exercise price of $0.93, vesting over 12 months.

Summary

• Linda Kozick, a Director of RAPT Therapeutics, Inc., acquired 257,832 stock options.
• The options have an exercise price of $0.93 per share.
• These options will vest in 12 equal monthly installments starting from May 29, 2025.
• The options have an expiration date of May 28, 2035.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive event as it aligns management's interests with shareholder value, providing an incentive for long-term performance. However, it is a routine compensation event and not indicative of extraordinary operational news.

Positives

• The grant of 257,832 stock options to Director Linda Kozick aligns her interests with long-term shareholder value.
• The options have a 10-year expiration period, providing a long-term incentive for the director.

Future Outlook

The stock options granted to Director Linda Kozick will vest in 12 equal monthly installments from May 29, 2025, indicating a future incentive structure tied to continued service and potential long-term value creation.

Industry Context

The grant of stock options to a director is a common practice in the biotechnology and pharmaceutical industry, serving as a key component of executive and director compensation packages to align their interests with long-term company performance and shareholder value.

Comparison to Industry Standards

• The grant of stock options as part of director compensation is a standard practice across publicly traded companies, including those in the biotechnology sector like RAPT Therapeutics.
• The specific number of options and exercise price would typically be benchmarked against peer companies of similar market capitalization and stage of development, though this document does not provide such comparative data.

Related Party Transactions

• The grant of stock options to Director Linda Kozick constitutes a related party transaction, which is a common and disclosed form of compensation for board members.

Stakeholder Impact

• Shareholders: The grant of stock options to a director aims to align their interests with long-term shareholder value, potentially leading to improved company performance.

Next Steps

• The stock options will continue to vest in 12 equal monthly installments from May 29, 2025.

Key Dates

Recommendation

Keywords

RAPT Therapeutics, RAPT, stock options, insider transaction, Form 4, beneficial ownership, director compensation, equity grant